- Excluding older, sicker patients from clinical trials: issues, concerns, and solutions1
- Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report1
- Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff1
- How better access to mental health care can reduce crime1
- How much do older workers value employee health insurance?1
- How nursing affects Medicare's outcome-based hospital payments1
- Humanitarian device exemption (HDE) program: guidance for industry and Food and Drug Administration staff1
- Improving quality and efficiency in health care through comparative effectiveness analyses: an international perspective1
- Incorporating costs into comparative effectiveness research1
- Increasing the value of health care: the role of nurses1
- Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report1
- Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report1
- Management of patients with opioid dependence: a review of clinical, delivery system, and policy options1
- Medicaid at 50: a look at the long-term benefits of childhood Medicaid1
- Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report1
- Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary1
- Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report1
- PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report1
- Palliative care in the outpatient setting: a comparative effectiveness report : final report1
- Pharmacogenomics: a primer for policymakers1